[go: up one dir, main page]

MA50424A - Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 - Google Patents

Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2

Info

Publication number
MA50424A
MA50424A MA050424A MA50424A MA50424A MA 50424 A MA50424 A MA 50424A MA 050424 A MA050424 A MA 050424A MA 50424 A MA50424 A MA 50424A MA 50424 A MA50424 A MA 50424A
Authority
MA
Morocco
Prior art keywords
ccr6
methods
cxcr2 antagonist
treating generalized
pustulous
Prior art date
Application number
MA050424A
Other languages
English (en)
Inventor
James J Campbell
Karen Ebsworth
Antoni Krasinski
Venkat Reddy Mali
Jeffrey Mcmahon
Rajinder Singh
Ju Yang
Chao Yu
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA50424A publication Critical patent/MA50424A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050424A 2018-01-08 2019-01-07 Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 MA50424A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614927P 2018-01-08 2018-01-08
US201862715503P 2018-08-07 2018-08-07

Publications (1)

Publication Number Publication Date
MA50424A true MA50424A (fr) 2020-08-26

Family

ID=67140280

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050424A MA50424A (fr) 2018-01-08 2019-01-07 Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2

Country Status (9)

Country Link
US (2) US11207294B2 (fr)
EP (1) EP3737366A4 (fr)
JP (1) JP7322036B2 (fr)
CN (1) CN111867579B (fr)
AU (1) AU2019205786B2 (fr)
IL (1) IL275839B2 (fr)
MA (1) MA50424A (fr)
TW (1) TWI821235B (fr)
WO (1) WO2019136370A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
EP4143179B1 (fr) 2020-04-30 2025-10-22 Idorsia Pharmaceuticals Ltd Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023072924A1 (fr) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
KR20240090693A (ko) 2021-10-28 2024-06-21 이도르시아 파마슈티컬스 리미티드 Ccr6 수용체 조절인자

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (fr) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Support pour medicaments a liberation progressive
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
CN1454204A (zh) 2000-05-30 2003-11-05 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
ATE346043T1 (de) 2001-01-16 2006-12-15 Smithkline Beecham Corp Il-8-rezeptorantagonisten
WO2002067919A1 (fr) 2001-01-16 2002-09-06 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8
IL156793A0 (en) 2001-02-02 2004-02-08 Schering Corp 3,4-di-substituted cyclobutene-1,2-diones as cxc chemokine receptor antagonists
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
CA2444031C (fr) 2001-04-16 2012-02-21 Schering Corporation Cyclobutene-1,2-diones a disubstitution en positions 3,4 utilisees comme ligands de recepteurs de la chimiokine cxc
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003080053A1 (fr) 2002-03-18 2003-10-02 Schering Corporation Traitements combines pour maladies induites par la chimiokine
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
CN100448860C (zh) 2003-04-18 2009-01-07 先灵公司 合成2－羟基－n,n－二甲基－3－[[2－[[1(r)－(5－甲基－2－呋喃基)丙基]氨基]－3,4－二氧代－1－环丁烯－1－基]氨基]苯甲酰胺
MXPA06008599A (es) 2004-01-30 2006-08-28 Schering Corp Polimorfos cristalinos de un ligando receptor de cxc-quimiocina.
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
TW200813033A (en) 2006-07-07 2008-03-16 Schering Corp 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor ligands
US7691851B2 (en) 2007-03-07 2010-04-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
BRPI0812222A2 (pt) 2007-06-06 2014-12-16 Novartis Ag Compostos ciclobutenodiona substituídos anti-inflamatórios.
CA2692269A1 (fr) 2007-07-03 2009-01-08 Schering Corporation Procede et intermediaires de synthese de composes de 3,4-dioxo-1-cyclobutene 1,2-substitues
JP2010532357A (ja) 2007-07-05 2010-10-07 シェーリング コーポレイション １，２−置換３，４−ジオキソ−１−シクロブテン化合物における制御された結晶サイズのための方法
WO2009012375A2 (fr) 2007-07-19 2009-01-22 Wyeth Inhibiteurs de la squarate kinase
WO2009042907A1 (fr) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
CN102123988B (zh) 2008-06-24 2013-08-14 顶标公司 作为烟酰胺抑制剂的方酸衍生物
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010045303A2 (fr) 2008-10-16 2010-04-22 Schering Corporation Dérivés de pyrrolidine, de pipéridine et de pipérazine et leurs méthodes d'utilisation
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
WO2010091543A1 (fr) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Nouveaux dérivés d'hydrazinocyclobut-3-ène-1,2-dione comme antagonistes de cxcr2
WO2010131146A1 (fr) 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
EP2760821B1 (fr) 2011-09-02 2017-10-11 Novartis AG Sel de choline d'un composé anti-inflammatoire à base de cyclobutènedione substitué
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
KR102038310B1 (ko) * 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
US9458174B2 (en) 2012-05-23 2016-10-04 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
WO2015170430A1 (fr) * 2014-05-08 2015-11-12 学校法人慶應義塾 Agent inhibiteur des troubles inflammatoires subséquents à une dissection aortique
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist

Also Published As

Publication number Publication date
TWI821235B (zh) 2023-11-11
CA3087701A1 (fr) 2019-07-11
EP3737366A4 (fr) 2022-07-27
US20220280481A1 (en) 2022-09-08
CN111867579B (zh) 2023-11-24
IL275839A (en) 2020-08-31
JP7322036B2 (ja) 2023-08-07
AU2019205786B2 (en) 2023-12-14
TW201936600A (zh) 2019-09-16
US11207294B2 (en) 2021-12-28
US11684606B2 (en) 2023-06-27
AU2019205786A1 (en) 2020-08-06
IL275839B1 (en) 2023-10-01
WO2019136370A2 (fr) 2019-07-11
CN111867579A (zh) 2020-10-30
IL275839B2 (en) 2024-02-01
JP2021510160A (ja) 2021-04-15
WO2019136370A3 (fr) 2020-04-16
US20190209527A1 (en) 2019-07-11
EP3737366A2 (fr) 2020-11-18

Similar Documents

Publication Publication Date Title
MA50424A (fr) Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
EP4052118A4 (fr) Réduction automatique d'ensembles d'instruction pour programmes d'apprentissage automatique
IL283463A (en) Automated generation of machine learning models
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3674983C0 (fr) Apprentissage machine pour inférence d'objet modélisé 3d
DK3822773T3 (da) Forbedret input af maskinlæringsacceleratoraktiveringer
EP3545471A4 (fr) Formation distribuée de flux de travaux cliniques de réseaux neuronaux à apprentissage profond
IL280174A (en) Highly purified fucans for the treatment of fibrous adhesions
EP3413963A4 (fr) Accès à un site de traitement intravasculaire
EP3773563C0 (fr) Promédicaments d'antagonistes de c5ar bicycliques fusionnés
EP3909062A4 (fr) Similarité de profilage génomique
EP3368041A4 (fr) Traitement du cancer du poumon à petites cellules avec un inhibiteur de parp
EP3545392A4 (fr) Optimisation automatique de signal tactile
EP3445450A4 (fr) Méthode de traitement ou de prévention d'états pathologiques hépatiques
EP3694504A4 (fr) Traitement de la glomérulosclérose segmentaire focale avec des antagonistes du ccr2
EP3834045A4 (fr) Prédiction de qualité de réponse courte
BR112016020366A2 (pt) anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais
IL283314A (en) Mutated piggybac transposase
IL287904A (en) Combination treatment of arthritic disease
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP4070336A4 (fr) Prédiction de la thrombo-embolie veineuse au moyen de modèles d'apprentissage automatique
EP3832456C0 (fr) Exécution de barrière d'outils externes pendant des changements de logiciel
IL282087A (en) Treatment of pruritus with p2x3 antagonists
PL3863759T3 (pl) Reaktor kawitacyjny i sposób jego wytwarzania
EP3867483C0 (fr) Marche auto-rétractable